Development continues

Isis plans to move 3521 into a 40-patient Phase III trial for treatment of non-small cell lung cancer by the second quarter of 2000. Phase I/II study data indicate that 3521 can be added to an active cancer regimen and raise efficacy without increasing toxicity, Isis said. Ongoing Phase II trials are evaluating 3521 in ovarian cancer, breast cancer and non-Hodgkin's lymphoma. Isis 5132 is in Phase II for breast and ovarian cancers, although data for 5132 is "less impressive" than 3521, Isis said